Pluri 2026 Q1 Earnings Narrowed Loss Per Share Amidst Wider Net Loss

Pluri (PLUR) reported fiscal 2026 Q1 earnings on Nov 13, 2025, with mixed results. The company narrowed its per-share loss by 39.8% to $0.65, a positive step, but its net loss widened to $6.13 million from $6.04 million year-over-year. Revenue declined 3.1% to $316,000, underscoring ongoing financial challenges.

Revenue

Total revenue for 2026 Q1 fell to $316,000, a 3.1% decline compared to $326,000 in the prior-year period. The drop reflects broader market headwinds and operational inefficiencies.

Earnings/Net Income

Pluri reduced its per-share loss to $0.65 from $1.08 year-over-year, a 39.8% improvement. However, the net loss expanded to $6.13 million, a 1.6% increase from $6.04 million. The company has posted losses for 10 consecutive years in this quarter, underscoring persistent financial strain. While the EPS improvement is a positive signal, the widening net loss highlights structural challenges.

Price Action

Post-earnings, Pluri’s stock price dropped 7.73% during the latest trading day, surged 28.62% in the preceding week, and declined 7.52% month-to-date. The volatility reflects investor uncertainty about the company’s long-term viability.

Post-Earnings Price Action Review

The stock’s sharp intraday decline, despite a weekly rebound, signals mixed investor sentiment. The 7.73% drop in the latest session aligns with the widened net loss, while the 28.62% weekly surge may reflect optimism over the 39.8% EPS improvement. Month-to-date, the 7.52% decline suggests lingering skepticism about the company’s ability to sustain profitability. The erratic price action underscores the stock’s high volatility and the market’s focus on near-term financial performance.

Additional News

Pluri launched Cellav Health and Aesthetics, a new subsidiary targeting the regenerative skincare market, in partnership with Miss Universe Skincare. This marks its entry into high-growth beauty sectors, with a product line expected in H1 2026. Additionally, the company expanded its foodtech and agtech collaborations across Asia, Europe, and the U.S., advancing cultivated meat, cell-based cacao, and cellular coffee initiatives. These strategic moves aim to diversify revenue streams and leverage its 3D cell-expansion platform.

CEO Commentary

Pluri’s CEO emphasized the Cellav launch as a strategic pivot to high-demand beauty markets, aligning with the company’s focus on near-term revenue. While the earnings report highlighted progress in narrowing per-share losses, the CEO acknowledged the need for sustained profitability.

Guidance

Pluri provided no formal guidance but reiterated its focus on scaling Cellav and foodtech ventures. The company aims to leverage partnerships for revenue growth, though its financial outlook remains constrained by operational losses and liquidity challenges.

Financial Health

Pluri’s financials show a 53.8% revenue growth over three years but negative operating margins (-1659.88%) and net margins (-1690.34%). Liquidity ratios (0.68) and a debt-to-equity ratio (-4.98) signal significant risks. Analysts remain cautious, citing speculative valuation metrics and sector volatility.